CA3026178C - Diprovocims: a new and potent class of tlr agonists - Google Patents
Diprovocims: a new and potent class of tlr agonists Download PDFInfo
- Publication number
- CA3026178C CA3026178C CA3026178A CA3026178A CA3026178C CA 3026178 C CA3026178 C CA 3026178C CA 3026178 A CA3026178 A CA 3026178A CA 3026178 A CA3026178 A CA 3026178A CA 3026178 C CA3026178 C CA 3026178C
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- pyrrolidine
- trans
- date received
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356314P | 2016-06-29 | 2016-06-29 | |
| US62/356,314 | 2016-06-29 | ||
| PCT/US2017/040028 WO2018005812A1 (en) | 2016-06-29 | 2017-06-29 | Diprovocims: a new and potent class of tlr agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3026178A1 CA3026178A1 (en) | 2018-01-04 |
| CA3026178C true CA3026178C (en) | 2024-05-21 |
Family
ID=60787607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3026178A Active CA3026178C (en) | 2016-06-29 | 2017-06-29 | Diprovocims: a new and potent class of tlr agonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11040959B2 (https=) |
| EP (1) | EP3445758B1 (https=) |
| JP (1) | JP6964298B2 (https=) |
| KR (1) | KR102522730B1 (https=) |
| CN (1) | CN109641878B (https=) |
| AU (1) | AU2017290238B2 (https=) |
| BR (1) | BR112018077397A2 (https=) |
| CA (1) | CA3026178C (https=) |
| IL (1) | IL263388B (https=) |
| WO (1) | WO2018005812A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164445A (zh) * | 2018-08-02 | 2021-07-23 | 得克萨斯系统大学评议会 | Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病 |
| JP2023527792A (ja) | 2020-05-27 | 2023-06-30 | アキシャル セラピューティクス，インク． | Ｔｌｒ２調節剤化合物、医薬組成物、及びそれらの使用 |
| US20250367166A1 (en) * | 2022-04-29 | 2025-12-04 | The Scripps Research Institute | Next generation diprovocims that activate the innate and adaptive immune response |
| US20260091126A1 (en) * | 2022-09-20 | 2026-04-02 | The Curators Of The University Of Missouri | Amino acid-modified lipids for rna delivery |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1418905T3 (da) | 2001-08-08 | 2007-09-10 | Pentraxin Therapeutics Ltd | Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma |
| WO2005016235A2 (en) * | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
| PE20071079A1 (es) | 2005-11-15 | 2007-12-16 | Cytokinetics Inc | Compuestos de piperidina como inhibidores de la proliferacion celular |
| AU2011232421B2 (en) | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| EP2958889B1 (en) | 2013-02-25 | 2017-03-22 | The Scripps Research Institute | Neoseptins: small molecule adjuvants |
| US9918959B2 (en) | 2014-08-06 | 2018-03-20 | The Board Of Regents Of The University Of Texas System | TLR-independent small molecule adjuvants |
-
2017
- 2017-06-29 KR KR1020197002820A patent/KR102522730B1/ko active Active
- 2017-06-29 BR BR112018077397A patent/BR112018077397A2/pt unknown
- 2017-06-29 EP EP17821259.3A patent/EP3445758B1/en active Active
- 2017-06-29 CN CN201780040830.9A patent/CN109641878B/zh active Active
- 2017-06-29 CA CA3026178A patent/CA3026178C/en active Active
- 2017-06-29 WO PCT/US2017/040028 patent/WO2018005812A1/en not_active Ceased
- 2017-06-29 JP JP2018568338A patent/JP6964298B2/ja active Active
- 2017-06-29 US US16/303,043 patent/US11040959B2/en active Active
- 2017-06-29 AU AU2017290238A patent/AU2017290238B2/en active Active
-
2018
- 2018-11-29 IL IL263388A patent/IL263388B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN109641878B (zh) | 2021-09-14 |
| WO2018005812A1 (en) | 2018-01-04 |
| KR20190014133A (ko) | 2019-02-11 |
| CA3026178A1 (en) | 2018-01-04 |
| IL263388A (en) | 2018-12-31 |
| JP6964298B2 (ja) | 2021-11-10 |
| EP3445758A1 (en) | 2019-02-27 |
| US11040959B2 (en) | 2021-06-22 |
| AU2017290238B2 (en) | 2021-02-18 |
| EP3445758A4 (en) | 2019-09-25 |
| BR112018077397A2 (pt) | 2019-10-01 |
| KR102522730B1 (ko) | 2023-04-19 |
| AU2017290238A1 (en) | 2018-12-13 |
| CN109641878A (zh) | 2019-04-16 |
| JP2019519574A (ja) | 2019-07-11 |
| IL263388B (en) | 2021-02-28 |
| EP3445758B1 (en) | 2020-11-04 |
| US20200207742A1 (en) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109415387B (zh) | 精氨酸酶抑制剂及其治疗应用 | |
| CA3026178C (en) | Diprovocims: a new and potent class of tlr agonists | |
| CA3220847A1 (en) | Protease inhibitors as antivirals | |
| CZ20032532A3 (en) | Drugs containing triazaspiro 5.5 undecane derivatives as the active ingredient | |
| US20150018340A1 (en) | Pipecolate-diketoamides for treatment of psychiatric disorders | |
| JP7767151B2 (ja) | プロドラッグ化合物 | |
| CZ39994A3 (en) | Synthetic aryl polyamines representing antagonists of excitation amino acid neurotransmitters, process of their preparation and use | |
| TW442469B (en) | Fibrinogen receptor antagonists having substituted β-amino acid residues and pharmaceutical compositions comprising the same | |
| CA3196221A1 (en) | Conjugated tlr7 and nod2 agonists | |
| IL324431A (en) | Anti-hiv compounds | |
| JPH024748A (ja) | 薬理作用を有するペプチド類 | |
| CA3177546A1 (en) | Tlr2 modulator compounds, pharmaceutical compositions and uses thereof | |
| US11352365B2 (en) | Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same | |
| US20250367166A1 (en) | Next generation diprovocims that activate the innate and adaptive immune response | |
| JP3874455B2 (ja) | フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220318 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250812 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250812 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260224 |